Early Assessment of the Response to Neo-adjuvant Chemotherapy in Breast Cancer Patients With FDG-PET

Early Assessment of the Response to Neo-adjuvant Chemotherapy in Breast Cancer Patients With FDG-PET

18F-FDG PET, a whole-body imaging technology based on glucose metabolism, can effectively detect subclinical and clinical therapeutic responses at stages that are earlier than those detected by conventional approaches.

We propose to conduct a prospective study to evaluate early therapeutic response using 18F-FDG PET before and after the 1st cycle of neo-adjuvant chemotherapy for breast cancer patients.

Variation of 18F-FDG PET uptake is compared to clinical and echographical tumor response evaluated after 3 cycles of chemotherapy.

The purpose is to estimate the capacity of 18F-FDG PET to differentiate responder and non-responder patients.

Further study details as provided by Centre Oscar Lambret

Inclusion Criteria:

• Age > 18
• Breast cancer treated by neo-adjuvant chemotherapy (T>2cm)
• Measurable lesions ,assessed clinically and by ultrasound
• Delay minimum between biopsy and PET: 15 days
• PS-WHO: 0

Exclusion Criteria:

• T<2cm
• Inflammatory breast cancer (T4d)
• Diabetic patients unbalanced (glycemia>1.40)
• Pregnant or lactating women